https://www.avient.com/sites/default/files/2024-12/Terms and Conditions of Sale for France.pdf
Within the limits of Article 5, Seller warrants good and clear title in goods subject to the sale
and that the Product conforms at the time of shipment to a Certificate of Analysis, a Certificate of Compliance, or a Product
Specification Sheet, if any such document exists, and other specifications signed by Seller (“Specifications”).
https://www.avient.com/sites/default/files/2023-01/Avient Audit Committee Charter.pdf
Review disclosures made to the Audit Committee by the Company’s CEO and CFO during their
certification process for reports on Form 10-K and Form 10-Q about any significant deficiencies
in the design or operation of internal controls and procedures or material weaknesses therein and
4
any fraud involving management or other employees who have a significant role in the
Company’s internal controls and procedures.
10.
https://www.avient.com/sites/default/files/2024-03/Terms and Conditions of Sale for South Africa.pdf
Seller warrants good and clear title in
goods subject to the sale (“Product”) and that the Product conforms
at the time of shipment to a Certificate of Analysis, a Certificate of
Compliance, or a Product Specification Sheet, if any such document
exists, and other specifications signed by Seller (“Specifications”).
https://www.avient.com/sites/default/files/2021-11/avient-design-ergonomic-design-guide.pdf
Figure 12: Duration of use
BMC Musculoskeletal Disorders 2021 22:186.
https://doi.org/10.1186/s12891-021-04054-6
Figure 11: Duration of use
Journal of Rehabilitation Medicine, 47 2 (2015): 154-60.
https://doi.org/10.2340/16501977-1897
https://doi.org/10.1186/s12891-021-04054-6
https://doi.org/10.2340/16501977-1897
https://www.semanticscholar.org/paper/Hand-grip-fatigability-in-persons-with-multiple-to-Severijns-Lamers/834a2a4e4665c6e9f3d7513507807314d0214828
Ergonomic Grip Design Guide 11
Pre-production validation of the conceptual design
is paramount in reducing the overall risk of the
program.
Common regulations
• REACH SVHC, RoHS 3 (EU 2015/863),
CA Prop 65, Heavy Metals (CONEG, 94/62/EC)
and Conflict Minerals
• Substances of Concern (could include
phthalates, latex, PVC, BPA, halogens, PAH,
flame retardants)
Other market-specific regulations
• Consumer Product Safety Improvement Act of
2008 (CPSIA)
- Lead and phthalate limits for products
designed for children
• Chemicals of High Concern for Children (CHCC)
- Several US states (OR, WA, VT, ME, MN) have
lists of chemicals of concern for products .
https://www.avient.com/sites/default/files/2023-07/AVNT Q2 2023 Earnings Press Release%5B43%5D.pdf
Registration information to access the Sustainability Day event will be provided in a news release
in advance of the event.
https://www.avient.com/sites/default/files/2021-10/avnt-q3-2021-news-release.pdf
We will be
sending out registration information shortly and will offer both in-person and virtual options in light
of the continuing impacts of the pandemic.”
https://www.avient.com/sites/default/files/2024-08/Avient Q2 2024 Earnings Call Presentation.pdf
FX +4.6%
FX -1.5%
Total Avient +3.1%
Note: Regional Sales Percentages exclude impact of foreign exchange
Q2 2024 SEGMENT PERFORMANCE
(COLOR, ADDITIVES & INKS)
$525
$542
$94
$108
19.9%
(in millions) (in millions)
7
17.9%
+200 bps
* Adjusted EBITDA Margin %
• Organic sales growth in all
regions led by Americas
• Raw material deflation combined
with cost reduction actions drove
EBITDA margin expansion
+ 3%
(+5% excluding FX)
+ 15%
(+17% excluding FX)
Q2 2024 SEGMENT PERFORMANCE
(SPECIALTY ENGINEERED MATERIALS)
$301
$308
$60
$64
20.6%
(in millions) (in millions)
8
19.8%
+80 bps
* Adjusted EBITDA Margin %
• Sales growth in consumer,
healthcare and building &
construction end markets offset
by weaker demand in
telecommunications
• EBITDA margin expansion
driven by positive end market
mix as well as raw material
deflation
+ 2%
(+4% excluding FX)
+ 7%
(+8% excluding FX)
2024 G U IDA N CE
FY 2024 GUIDANCE
Previous (May 7) Current
Adjusted EBITDA $510 to $535 million $515 to $540 million
Adjusted EPS $2.50 to $2.65 $2.55 to $2.70
Interest Expense $105 million $105 million
Adjusted Effective Tax Rate 23% to 25% 23% to 25%
Capital Expenditures ~$140 million ~$140 million
10
Q3 2024: Adjusted EPS of $0.62
11
Highlights
• Provides performance updates on 2030
Sustainability Goals
• Reduced company’s Scope 1 & 2 GHG emissions
by 48% since 2019
• Highlights ESG performance ratings, certifications,
and awards, including recent upgrades by
Ecovadis to Gold and CDP to A-
• Reflects Great Place to Work® culture focused on
health, safety and employee engagement
2023 SUSTAINABILITY REPORT
11
Sustainability for a
Better Tomorrow
2023
SUSTAINABILITY REPORT
12
• Investor Day to be held December 4, 2024 in
New York, NY
• The focus will be to do a deep dive on the
Company’s strategy
• Further details to be communicated
2024 AVIENT INVESTOR DAY
AP P EN D IX
15
Performance
Additives
15%
Pigments
TiO2
Dyestuffs
Polyethylene
10%Nylon
Polypropylene
Styrenic Block
Copolymer
Other Raw
Materials
38%
~40% hydrocarbon based
(Grey shaded materials are hydrocarbon based,
includes portion of “Other Raw Materials”)
Non-hydrocarbon
based materials
RAW MATERIAL BASKET
SEGMENT DATA
U.S. & Canada
41%
36%
2023 SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
19%
23%Industrial
Building and
7%
END MARKET REVENUE
$2,007M $358M
$1,138M $224M
Sales EBITDA
Specialty Engineered Materials
Color Additives and Inks
$502M$3,143M
(1)
7%
17
(1) Total company sales and adjusted EBITDA of $3,143M and $502M, respectively, include intercompany sales eliminations and corporate costs
2023 REVENUE | $2 .0 B ILL ION
34%
37%
21%
END MARKET REGION
18
34%
21%
15%
Building &
1% Energy
COLOR, ADDITIVES & INKS
2023 REVENUE | $1 .1 B ILL ION
52%
35%
19
6%Industrial
12%
10% Defense
Building &
END MARKET REGION
SPECIALTY ENGINEERED MATERIALS
32%
26%
Building &
6%
2% Defense
1%
(18% of sales)
2023 AVIENT REGIONAL SALES
25%
Building &
(36% of sales)Transportation
22%
Building &
12%
6%
US &
Canada
(41% of sales)
59%
22%
Building &
LATAM
(5% of sales)
20
BY END MARKET
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/news/archives?page=17
Avient Achieves Reexamination Certificate for Dyneema® Cut-Resistant Yarn Patent
Avient Showcases New Sustainable Solutions and Recent Compliance Certifications at ITMA 2023
https://www.avient.com/investor-center/news/avient-announces-third-quarter-2024-results
Registration details will be released shortly.
https://www.avient.com/sites/default/files/2024-03/AVNT February IR Presentation_w_Non-GAAP Recs_v2.pdf
ASHISH KHANDPUR
PRESIDENT & CEO
7
8
PORTFOLIO TRANSFORMATION
8
46%
66%
87%
100%
0%
20%
40%
60%
80%
100%
2005 2010 2015 2020 2023
%
o
f A
dj
us
te
d
EB
IT
D
A
Commodity JVs Distribution Performance Products & Solutions Specialty Businesses
Adjusted EBITDA from Specialty Applications
SUSTAINABILITY AS A GROWTH DRIVER
9
LONG-TERM REVENUE GROWTH DRIVERS
Sustainable
Solutions
Composites, Healthcare,
Asia / LATAM
Overlap
Other
60%+
Key Growth
Drivers
Total Company Revenue
Growth Drivers Long-Term
Growth Rate
Sustainable Solutions 8–12%
Composites 8–10%
Healthcare 8–10%
Asia / LATAM 5%
Other 0–2%
Avient 6%
END MARKET OBSERVATIONS
(% OF COMPANY SALES)
ENERGY
DEFENSE
TELECOMMUNICATIONS
HEALTHCARE
10
TRANSPORTATION
INDUSTRIAL
BUILDING &
CONSTRUCTION 9%
CONSUMER
PACKAGING
23%
11
REGIONAL OBSERVATIONS
(% OF COMPANY SALES)
11
Q 4 2023 RE S U LT S
Q4 2023 PERFORMANCE VS.